Title

Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia
A 3 Weeks Open Label Study to Evaluate the Efficacy in Agitation and Safety of Quetiapine Fumarate XR in Treatment of Patients With Acute Schizophrenia
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Intervention/Treatment

    quetiapine ...
  • Study Participants

    35
The purpose of the study is to determine whether treatment with quetiapine XR (Seroquel XR) tablets for 3 weeks will improve their agitation when they have acute psychosis.
Study Started
Sep 30
2009
Primary Completion
Mar 31
2010
Study Completion
Apr 30
2010
Results Posted
Jan 08
2013
Estimate
Last Update
Jan 08
2013
Estimate

Drug Quetiapine XR (Seroquel XR)

Tablet, oral, once daily

  • Other names: Seroquel XR

Quetiapine XR Experimental

Quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards.

Criteria

Inclusion Criteria:

Requirement for treatment of acute episode of schizophrenia (according to DSM-IV diagnostic criteria)
PANSS total score of ³ 75
CGI > 4

Exclusion Criteria:

Any DSM-IV (Diagnostic and Statistical Manual of Mental Disorders 4th Edition) Axis I disorder not defined in the inclusion criteria
Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
Substance or alcohol dependence at enrollment

Summary

Quetiapine Fumarate XR

All Events

Event Type Organ System Event Term Quetiapine Fumarate XR

Change From Baseline in Positive and Negative Syndrome Scale Excited Component (PANSS-EC) Score

PANSS- Excited Component (EC) subscale score will be calculated by adding together the following item scores: excitement (positive subscale item 4); hostility (positive subscale item 7); tension (general subscale item 4); uncooperativeness (general subscale item 8); poor impulse control (general subscale item 14). This is rated on a 7-point Likert scale from 'absent' to 'extremely severe' (score range 5 to 35 points; mean scores = 20 points clinically corresponds to severe agitation). Lower value gives the better outcome.

Quetiapine Fumarate XR

-7.5
Scores on a scale (Mean)
Standard Deviation: 4

Change From Baseline to Final Visit at Day 21 in PANSS Positive, General Psychopathological Scores.

Positive scale includes 7 Items (Delusions, Conceptual disorganization, Hallucinations, Hyperactivity, Grandiosity, Suspiciousness/persecution, Hostility)and is calculated by adding the positive subscale item scores. Minimum score is 7, maximum score is 49. General Psychopathology scale:16 items (Somatic concern, Anxiety, Guilt feelings, Tension, Mannerisms and posturing, Depression, Motor retardation, Uncooperativeness, Unusual thought content, Disorientation, Poor attention, Lack of judgment and insight, Disturbance of volition, Poor impulse control, Preoccupation, Active social avoidance). Minimum score is 16, maximum score is 112. The higher score- the worse outcome. The biggest reduction of score from baseline- a better efficacy. Measure includes PANSS-Positive (range 8-30), PANSS-General Psychopathological (PANSS-G)(range 17-70), total PANSS score (range 37-143), PANSS aggression, hostility and depression cluster scores (range 4-19).

Quetiapine Fumarate XR

-9.3
Scores on a scale (Mean)
Standard Deviation: 5.5

Change From Baseline to Final Visit at Day 21 in PANSS Negative, General Psychopathological Scores

Negative scale includes 7 items (Blunted affect, Emotional withdrawal, Poor rapport, Passive/apathetic social withdrawal, Difficulty in abstract thinking, Lack of spontaneity and flow of conversation, Stereotyped thinking)and is calculated by adding the negative subscale item scores. Minimum score is 7, maximum score is 49. General Psychopathology scale includes 16 Items (Somatic concern, Anxiety, Guilt feelings, Tension, Mannerisms and posturing, Depression, Motor retardation, Uncooperativeness, Unusual thought content, Disorientation, Poor attention, Lack of judgment and insight, Disturbance of volition, Poor impulse control, Preoccupation, Active social avoidance). Minimum score is 16, maximum score is 112. The higher score- the worse outcome. Measure includes PANSS-Negative (range 8-37), PANSS-General Psychopathological (PANSS-G)(range 17-70), total PANSS score (range 37-143), PANSS aggression, hostility and depression cluster scores (range 4-19).

Quetiapine Fumarate XR

-5.7
Scores on a scale (Mean)
Standard Deviation: 4.9

Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score

Positive and Negative Syndrome Scale (PANSS) total score is a medical scale used for measuring symptom severity of patients with schizophrenia. It is calculated by adding together PANSS-Positive (minimum score = 7, maximum score = 49, PANSS-Negative (minimum score = 7, maximum score = 49), PANSS-General Psychopathological (PANSS-G) subscale scores (minimum score = 16, maximum score = 112), supplementary subscale item scores. The minimum is 30, maximum is 210. Total PANSS score classification: Mildly ill 58- 74, Moderately ill 75-94, Markly ill 95- 115, Severely ill >116.

Quetiapine Fumarate XR

-33.2
Scores on a scale (Mean)
Standard Deviation: 21.3

Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S)

Clinical Global Impression, Severity (CGI-S) is a single-item (7-point) scale that evaluates the overall severity of the subject's mental illness. A reduction in score indicates an improvement in the subject's condition. The CGI-S assessment should be based upon the subject's symptoms during the previous week. Change from baseline in CGI-S score is calculated by subtracting the CGI-S score at baseline from the CGI-S score at the relevant time point.

Quetiapine Fumarate XR

-1.2
scores on a scale (Mean)
Standard Deviation: 0.9

Change From Baseline in Absolute Clinical Global Impression-Improvement (CGI-I) Scale

Clinical Global Impression, Improvement (CGI-I) is a single-item (7-point) scale that evaluates the overall improvement in the subject's mental. A reduction in score indicates an improvement in the subject's condition. This assessment is based on the improvement since initiation of the study treatment. Change in CGI-I score is analyzed by comparing CSI-score at the relevant time point to the baseline CGI-I score.

Quetiapine Fumarate XR

Baseline

3.9
Scores on a scale (Mean)
Standard Deviation: 0.4

Day 21

2.4
Scores on a scale (Mean)
Standard Deviation: 1.2

Change of the Positive and Negative Syndrome Scale Excited Component (PANSS-EC) Score Compared From Baseline to Day 21.

Excited Component was used to evaluate the control of agitation and aggression in patients with schizophrenia. Difference in mean score at baseline and day 21 is used to assess the improvement. It is shown by reduction in mean score and confirmed by p value lower than 0,05. Positive and Negative Syndrome Scale Excited Component (PANSS-EC) is a subscale score which is calculated by adding together the following item scores: excitement (positive subscale item 4); hostility (positive subscale item 7); tension (general subscale item 4); uncooperativeness (general subscale item 8); poor impulse control (general subscale item 14). This is rated on a 7-point Likert scale from 'absent' to 'extremely severe' (score range 5 to 35 points; mean scores = 20 points clinically corresponds to severe agitation).

Quetiapine Fumarate XR

-33.2
Scores on a scale (Mean)
Standard Deviation: 21.3

Age Continuous

38.3
years (Mean)
Standard Deviation: 11

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

Quetiapine Fumarate XR

Drop/Withdrawal Reasons

Quetiapine Fumarate XR